If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humalog®
- Full Prescribing Information
Humalog® U-100 (insulin lispro injection)
100 units/mL - Full Prescribing Information
Humalog® U-200 (insulin lispro injection)
200 units/mL - Full Prescribing Information
Humalog® MIX50/50™ (50% insulin lispro protamine suspension 50% insulin lispro injection [rDNA origin])
100 units/mL - Full Prescribing Information
Humalog® MIX75/25™ (75% insulin lispro protamine suspension 25% insulin lispro injection [rDNA origin])
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
HUMALOG® (insulin lispro): Changing From Other Mealtime Insulin Products
Dose adjustment may be needed when transitioning from another insulin to Humalog (insulin lispro).
Dose adjustment may be needed when transitioning from another insulin to Humalog® (insulin lispro). Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased (Humalog Package Insert, 2015).
Enclosed Prescribing Information
HUMALOG® (insulin lispro injection), for subcutaneous or intravenous use, Lilly
The published reference below is available upon request by contacting 1-800-LillyRx.
Reference
Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.
Date of Last Review: March 18, 2017
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
